Background: Histologic transformation (HT) is a poorly understood event in patients with marginal zone lymphoma (MZL). The aim of this study was to analyze incidence and risk factors for HT in a large series of MZL patients.
introduction
Marginal zone lymphomas (MZLs) represent a group of indolent B-cell lymphomas that are derived from the marginal zone of the secondary lymphoid follicles and include three entities with a defined clinical and histologic pattern: extranodal MZL of mucosa-associated lymphoid tissue lymphoma (commonly termed MALT lymphoma) [1] , splenic MZL (SMZL) [2] and nodal MZL (NMZL) [3] . MZLs generally have an indolent course and favorable outcome [4] [5] [6] , yet a subset of patients may experience an adverse course of disease [7] . The reported median survival is >12 years in MALT lymphoma and ∼8 years in NMZL and SMZL [8] , in whom a proportion of cases may have a more aggressive clinical course [9, 10] . Histologic transformation (HT) and additional malignancies have been reported to be the leading risk factors for an unfavorable outcome in MZL [7] . However, the information concerning HT of MZL into aggressive entities is thus far very limited [11] .
The purpose of this study was to retrospectively analyze the clinical variables at diagnosis and the outcome, with special reference to HT into aggressive subtypes, in a population of consecutive patients with confirmed diagnosis of MZL.
patients and methods
The electronic databases of all non-Hodgkin lymphoma cases treated at the Oncology Institute of Southern Switzerland (IOSI) and at the Division of Hematology of the Amedeo Avogadro University of Eastern Piedmont were used to identify the study population. These databases include 2774 records consecutively diagnosed from 1980 to 2012, and have a common structure as previously reported [12] .
The present analysis focused on MZL diagnosed after the first recognition in the REAL classification of the separate entities now included in the WHO classification: MALT lymphomas, SMZLs and NMZLs [1] [2] [3] . Based on these criteria, 340 MZLs [13] were included in the analysis. A proportion of patients (with the disease confined to the bone marrow, with or without detectable peripheral blood involvement) could not be properly classified into any of the three MZL WHO classification subtypes and were considered clonal B-cell lymphocytosis of marginal zone origin (CBL-MZ), according to a recently published definition [14] .
HT was defined by a biopsy-proven transformation of previous MZL into an aggressive entity. Cases in which HT was only suspected because of an aggressive clinical behavior or cytological assessment, without histologic confirmation, were not taken into consideration in the present analysis. Cases with initial diagnosis of histologically aggressive lymphoma and concomitant indolent MZL were not included.
According to the revised response criteria for malignant lymphomas [15] , overall survival (OS) is defined as the time from diagnosis until death as a result of any cause; cause-specific survival (CSS) is defined as the time from diagnosis to death as a result of lymphoma; progression-free survival (PFS) is defined as the time from diagnosis until lymphoma progression or death as a result of any cause. Statistical analysis was conducted using the Stata Release 11 statistical software (Stata Corp. 2009, College Station, TX, USA). Follow-up was calculated as the median time to censoring using a reverse Kaplan-Meier analysis [16] . Survival probabilities were calculated using the life table method and survival curves were estimated by the Kaplan-Meier method; differences between curves were analyzed using the Wilcoxon test. Binomial exact 95% confidence intervals (95% CIs) were calculated for incidence percentages. Table 1 . Among the 157 MALT lymphomas, 72 patients had a primary gastric lymphoma. The ocular adnexae (n = 25) and the skin (n = 21) were the most common primary extragastric sites, followed by the lungs (n = 8) and the salivary glands (n = 6); no other sites included more than five patients. Fortyeight patients with MALT lymphoma had multiple extranodal sites of disease involvement.
Information about frontline treatment was available in 338 of 340 patients (Table 2) . One hundred and thirty-two (39%) asymptomatic patients (without rapidly growing lymphadenopathy, compression symptoms or vital organ failure) underwent expectant management (watchful waiting), defined as deliberate nonintervention for at least 3 months after diagnosis. The median duration of the expectant strategy was 27 months (interquartile range: 9-48 months). Treatment was administered, according to the protocol used at the time, to 29 of the patients initially managed expectantly, whereas 206 (61%) were treated immediately.
general outcome
Median OS and PFS of the whole population were 14.5 years (interquartile range: 7 years-not reached) and 5 years (interquartile range: 2-13 years), respectively ( Figure 1 ). With a median follow-up of 4.8 years (interquartile range: 2-9 years), 68 deaths were recorded, 7 of them due to a second cancer and 24 to lymphoma-related or treatment-related causes. CSS at 5 and 10 years was 93% (95% CI 89%-96%) and 84% (95% CI 75%-90%), respectively ( Figure 1 ). The International Prognostic Index (IPI) [17] stratification described the patient risk with respect to OS, CSS and PFS (all P-values <0.0001). In our cohort, we had 40 patients (19 with MALT lymphoma, 8 with splenic MZL, 5 with nodal MZL and 8 with CBL-MZ) who had additional cancers diagnosed either before or after the MZL. These patients had a significantly poorer outcome (median OS, 8.2 versus 14.5 years, P = 0.0035), all their second malignancies being solid cancer with the sole exception of a mantle cell lymphoma, which was considered as clonally unrelated with the MZL based on a divergent immunophenotype, including expression of cyclin-D1.
histologic transformation
After a median follow-up of 4.8 years, HT was observed in 13 cases (3.8%, 95% CI 2%-6.5%). All HT cases were histologically proven. Three of 13 HT were observed in the subgroup of patients with other cancers at a rate which was somewhat higher but not significantly different from the one observed in the MZL patients without additional malignancies (7.5% versus 3.3%, P = 0.187). In these three patients, second solid tumors were reported, affecting the kidney, the breast and the skin.
The main features of the patients who underwent HT are summarized in Table 3 .
Transformation into a diffuse large B-cell lymphoma (DLBCL) was documented in 12 patients, (among them, a 'triple-hit lymphoma' was reported due to the documented presence of the rearrangement of c-MYC, BCL6 and BCL2), whereas in one case the diagnosis was of classical Hodgkin lymphoma (cHL). A coexisting low-grade component was reported in the context of the same specimen that led to the diagnosis of HT in two cases (one DLBCL and one cHL), whereas, in two additional cases, an indolent component was reported in the bone marrow biopsy taken at the time of HT.
HT occurred after a median interval of 2.8 years (range: 1-12 years) after diagnosis. With respect to MZL subtype, HT occurred in 5% of SMZLs (4 cases), in 4% of MALT lymphomas (6 cases), in 3% of NMZLs (1 case) and in 3% of CBL-MZ (2 cases; P = 0.974). The risk of HT was 5% (95% CI 3%-9%) at 5 and 10 years after diagnosis and 10% (95% CI 5%-20%) at 12 years (Figure 2 ). At the time of HT, most patients had high lactate dehydrogenase (LDH) serum levels (7 of 10 of whom data were available) and B symptoms (5 of 9 of whom data were available). Clinical features of the whole cohort, as well as of the patients undergoing HT, are given in Table 3 . After transformation, nine patients received anthracycline-containing regimens, and three patients were treated with high-dose cytarabine regimens; only in a single patient supportive measures were adopted. In four patients, autologous stem cell transplantation was carried out (Table 4) . Therapeutic strategies were mainly based on patients' age and performance status (PS).
With a median post-transformation follow-up time of 12 months, 4 of 13 patients died, all for lymphoma-related causes, with a 2-year post-transformation survival rate of 57% (95% CI 13%-86%). Patients with HT did not appear to have a significantly shorter OS from the time of initial MZL diagnosis in comparison with those who did not experience HT (11.9 versus 14.5 years).
Several clinico-pathological variables at diagnosis were evaluated at univariate analysis for prognostic impact on the risk of One patient underwent autologous stem cell transplantation because of HT at the time of disease progression after an initial watchful waiting strategy. HT (sex, PS, B symptoms, serum LDH, serum β2-microglobulin, hepatitis C virus serology, bone marrow involvement, leukemic component, presence of extranodal disease or number of extranodal sites of localization, presence of bulky disease, Ann Arbor stage and risk according to the IPI). Among these, only elevated LDH serum level at diagnosis was significantly associated with a higher risk of HT (P = 0.0017). With respect to the frontline treatment strategies, no specific treatment approach at diagnosis, including a 'wait and see' approach, significantly appeared to have an impact on the risk of HT.
discussion
The present study is based on the retrospectively collected clinical records of patients diagnosed and treated at two centers across two decades. Despite the obvious limitations of a retrospective analysis, the study provides a picture of the clinical relevance of HT (all biopsy-confirmed in this series) among MZLs and might help further research in the field.
To our knowledge, our cohort is one of the largest populations of consecutive MZL patients in whom frequency, pattern and risk factors for HT have been studied. In this cohort, HT occurred in 13 of 340 cases (3.8%), a rate lower than the one (13% at 5 years) we found in follicular lymphoma (FL) [18] , despite a similar biopsy policy. No specific MZL histologic subtype appeared to be significantly associated with a higher risk of HT, in keeping with another recent report [7] .
With respect to MZL, variable rates of HT have been reported in the literature. One recent retrospective survey, which tested the transformation into aggressive lymphomaas well as the occurrence of additional malignancies-as independent risk factors for a shortened OS, reported a HT in 12% of the 197 MZL patients with a median follow-up of 4.5 years [7] . There are no clear explanations for the discrepancy in the HT rate between our results and this report, which identified a good-risk group of MZL patients lacking LDH elevation, HT and/or additional malignancies. A significantly longer OS in this subset of patients was also present in our series (data not shown).
Other previously published series focused on SMZL, including in most cases a limited number of patients, reported a risk of transformation into DLBCL ranging from 8 to 19% [19] [20] [21] [22] .
It is arguable that, in some series of MZL, the phenomenon of HT might be overestimated due to the frequent representation of scattered blasts (large cells) in the context of low-grade MZL lesions, not necessarily indicating a histologic evolution into aggressive entities [1] . All transformed cases were revised by an expert hematopathologist.
Another possible explanation is a referral bias. Nearly all cases diagnosed in our geographic area were referred to our institutions in the examined period; however, in other countries, patients with HT may have had a higher chance of being treated at tertiary hospitals and oncology centers.
Nevertheless, in a prospective randomized clinical trial involving newly diagnosed MALT lymphoma patients, after a median follow-up of 62 months, only 6 of the 227 patients of the analysis (3%) underwent HT [23] . In our series, as well as in the Meyer study [7] , HT represented in most cases an early event, occurring at the time of first disease relapse or progression, thus suggesting the presence of a patient subset prone to this kind of evolution and possible biological differences in MZL in patients destined to transform. Comparing the HT rate in MZLs, FL and chronic lymphocytic leukemia (CLL), the pattern of transformation in MZLs is closer to that of CLL transforming to Richter's syndrome, whose cumulative risk of transformation at 10 years is estimated 12%, whereas in FL it increases to 27% [11, 18, 24, 25] . Interestingly, in CLL, FL and MZL, the curves tend to reach a plateau, suggesting that there may be a portion of patients that will never undergo HT in all indolent subtypes [11, 18, 24, 25] .
Both in CLL and FL, post-transformation survival is generally poor [11, 18, 24, 25] . In the above-mentioned study by Meyer et al. [7] , MZL patients with either second malignancy or HT have a significantly shorter survival. In our report, 4 of 13 patients died, after HT, all for lymphoma-related causes, with a 2-year posttransformation survival rate of 57%. However, the small number of observed events and the relatively short follow-up prevent a definite analysis of survival after HT.
Among the clinico-pathological variables analyzed at diagnosis, only elevated LDH serum levels were significantly associated with the risk of HT. No specific therapeutic approach, including watchful waiting, predicted the risk of HT.
Another important issue concerns the definition of HT. In our report, HT was defined by a tissue biopsy-proving transformation of previous MZL into any aggressive entity. Cases in which HT was only suspected because of an aggressive clinical behavior or cytological assessment without histologic confirmation were not taken into consideration. In our series, a diagnosis of DLBCL was documented in 12 patients undergoing HT, whereas in one case, at the time of transformation, the diagnosis was of cHL. Transformation into aggressive clinical entities other than DLBCL is described also in CLL with 1-5% of cases transforming into cHL [26] .
Our series included 61 cases presenting as CBL-MZ [14] , a condition considered very indolent in which aggressive staging and therapeutic policies are not recommended [14, 27] . The inclusion of these cases could be another reason for the low HT rate in our series. Nevertheless, the rate of HT in CBL-MZ was not significantly lower than the one we observed in the other subtypes. A clinical progression was observed in 8 of 61 CBL-MZ, and HT was present at progression in 2 of them after a median follow-up of 3.5 years. Notably, the possibility of evolution toward a more aggressive histology was already described in CBL-MZ in the study that first defined this condition, which reported a patient developing a cutaneous DLBCL [14] .
In FL, several discrete molecular events have been described to result in HT [28] . The molecular pathogenesis of Richter syndrome in CLL is also characterized by a variety of heterogeneous mechanisms at both the genetic and epigenetic levels [29] . Differently from FL and CLL, the knowledge of the molecular bases of HT in MZL is still extremely limited. Further investigations will be required to understand whether different underlying mechanisms may also affect the frequency and clinical outcome of HT in the different indolent lymphoma types. 
